Cambium Bio Limited (ASX:CMB)

Australia flag Australia · Delayed Price · Currency is AUD
0.2150
0.00 (0.00%)
At close: Jul 7, 2025, 4:00 PM AEST
-46.25%
Market Cap 5.48M
Revenue n/a
Net Income n/a
Shares Out 18.28M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,002
Average Volume 11,850
Open 0.2150
Previous Close 0.2150
Day's Range 0.2150 - 0.2150
52-Week Range 0.1900 - 0.6800
Beta -0.24
RSI 72.39
Earnings Date n/a

About Cambium Bio

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. Its lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus for wound healing indications. Cambium Bio Limited is based in Paddington, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol CMB
Full Company Profile

News

There is no news available yet.